Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Satellos Bioscience Inc > How Long Can Immune Hold This Down?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(7)
•••
Comment by mmayeron Nov 23, 2017 9:25am
72 Views
Post# 27017785

RE:How Long Can Immune Hold This Down?

RE:How Long Can Immune Hold This Down?Timing... sure... in 20 years, you will make 10% profit!

SchiffKnowsBest wrote: Looks to me like someone is trying to sit on the share price and I guess just a coincidence that Immune raised $18M USD exactly a month ago today.....You'd almost think they had plans to buy-out ICO!  Especially given they likely know their licensed product from ICO will be a success (currently in phase II) and as a result will be forced to fork-over $32M USD in milestone payments......Why not offer half of that ($16M USD or 20 cents/share) and forego the milestone payments and get the bonus of AmpB enterring phase I.  Truly a no-brainer for Immune....Just a matter of timing.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities